Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network (Q38392332)

2 September 2017

1 reference

title

Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network (English)

1 reference

2 September 2017

1 reference

The Cancer Genome Atlas

1 reference

inferred from title

gastric adenocarcinoma

1 reference

2

Heinz-Josef Lenz

1 reference

2 September 2017

Yu Sunakawa

1

1 reference

2 September 2017

publication date

1 April 2015

1 reference

Current Treatment Options in Oncology

2 September 2017

published in

1 reference

2 September 2017

volume

16

1 reference

2 September 2017

issue

4

1 reference

2 September 2017

page(s)

17

1 reference

Molecular classification of gastric cancer: a new paradigm

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Epidemiology of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Helicobacter pylori infection in intestinal- and diffuse-type gastric adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Large-scale characterization of DNA methylation changes in human gastric carcinomas with and without metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Epstein-Barr virus in gastric carcinomas and gastric stump carcinomas: a late event in gastric carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Comprehensive molecular characterization of gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Mutations of PIK3CA in gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

The prevalence of PIK3CA mutations in gastric and colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

NVP-BEZ235 as a new therapeutic option for sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Involvement of JAK2 upstream of the PI 3-kinase in cell-cell adhesion regulation by gastrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Human gastrin mRNA expression up-regulated by Helicobacter pylori CagA through MEK/ERK and JAK2-signaling pathways in gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Chemosensitivity and survival in gastric cancer patients with microsatellite instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Oncogenic mutations in gastric cancer with microsatellite instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

BRAF and KRAS mutations in stomach cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

DNA binding properties of the yeast Msh2-Msh6 and Mlh1-Pms1 heterodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

DNA binding by yeast Mlh1 and Pms1: implications for DNA mismatch repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Oncogenic ERBB3 mutations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

HER2 therapy: molecular mechanisms of trastuzumab resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Cohort study based on the seventh edition of the TNM classification for gastric cancer: proposal of a new staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Histotype-based prognostic classification of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

E-cadherin germline mutations in familial gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Promoter DNA hypermethylation in gastric biopsies from subjects at high and low risk for gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

An SH3 domain-containing GTPase-activating protein for Rho and Cdc42 associates with focal adhesion kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Gastric and intestinal claudin expression at the invasive front of gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Epidermal growth factor receptor structural alterations in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0331-Y

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

21 January 2018

1 reference

12 December 2020

HER3 and mutant EGFR meet MET

1 reference

12 December 2020

Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance

1 reference

12 December 2020

The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma: an attempt at a histo-clinical classification

1 reference

12 December 2020

The role of mismatch repair in DNA damage-induced apoptosis.

1 reference

12 December 2020

Epstein-Barr virus and gastric carcinoma

1 reference

12 December 2020

Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes

1 reference

12 December 2020

Heterogeneous expression of claudin-4 in human colorectal cancer: decreased claudin-4 expression at the invasive front correlates cancer invasion and metastasis

1 reference

12 December 2020

Microsatellite alterations in adenoma and differentiated adenocarcinoma of the stomach

1 reference

12 December 2020

Predictive value of CHFR and MLH1 methylation in human gastric cancer

1 reference

12 December 2020

Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs

1 reference

12 December 2020

Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression.

1 reference

12 December 2020

Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease

1 reference

12 December 2020

Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma.

1 reference

12 December 2020

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial

1 reference

12 December 2020

Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy

1 reference

12 December 2020

Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy

1 reference

12 December 2020

The role of DNA mismatch repair in platinum drug resistance

1 reference

12 December 2020

1 reference

12 December 2020

10.1007/S11864-015-0331-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1037178045

0 references

1 reference